comparemela.com

Latest Breaking News On - Onxeo sa euronext - Page 1 : comparemela.com

Onxeo S A : Onxeo Changes Its Name and Becomes Valerio Therapeutics Following Approval by the Annual General Meeting of June 6, 2023

All the resolutions approved by the Board of Directors were adopted Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company

Mecklenburg vorpommernFrance generalShefali agarwalOnxeo sa euronextNicolas treboutaArthur rouillRobert colemanNicolas fossiezStefan klotterCompany groupEuronext growth parisAnnual general meetingValerio therapeuticChief executive officerGeneral meetingGeneral meetings

Onxeo : changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023

All the resolutions approved by the Board of Directors were adopted Paris , June 6, 2023 - 6:30 pm CEST - Onxeo S.A. , a clinical-stage biotechnology company specializing in. | June 6, 2023

France generalRobert colemanNicolas treboutaOnxeo sa euronextEuronext growth parisAnnual general meetingValerio therapeuticOnxeo stock exchangePress releasePecializing alonx fr0010095596

Onxeo Changes Its Name and Becomes Valerio Therapeutics Following Approval by the Annual General Mee

All the resolutions approved by the Board of Directors were adoptedPARIS (BUSINESS WIRE) Regulatory News:Onxeo S.A. (Euronext Growth Paris: ALONX), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and dr.

France generalRobert colemanNicolas treboutaNicolas fossiezArthur rouillShefali agarwalOnxeo sa euronextCompany groupRegulatory newsEuronext growth parisAnnual general meetingValerio therapeuticChief executive officerGeneral meetingGeneral meetings

Onxeo S A : Onxeo: Combined General Meeting of June 6, 2023: Availability of Preparatory Documents and Participation & Voting Procedures

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and

France generalOnxeo sa euronextOnis onxeoArthur rouillNicolas fossiezGewinn nurRaymond poincarRenaissance paris nobel tour eiffel hotelCompany groupRegulatory newsEuronext growth parisCombined general meetingGeneral meetingGeneral meetingsInvestor relations

Onxeo S A : Onxeo: Publication of the 2022 Annual Financial Report

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting

France generalOnxeo sa euronextNicolas fossiezArthur rouillRegulatory newsEuronext growth paris

vimarsana © 2020. All Rights Reserved.